Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Arrivent Biopharma Inc (AVBP)

136 + Investors. Track Smart Money conviction in AVBP. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%

136+

Inst. Holders

Hedge Fund Ownership: AVBP

How many hedge funds hold AVBP — quarterly history vs. share price
Quarterly hedge fund ownership of AVBP vs. share price

Market Analysis: AVBP

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: AVBP

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Arrivent Biopharma Inc (AVBP) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much AVBP has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 31d ago
AVBP
-11.7%
XLV
+3.1%

AVBP outperformed XLV by -14.8% since June 30, 2026.

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

18 top-rated funds 1 high-conviction
Consensus
5.6
/ 10
breadth
×
Elite
1.6
/ 10
conviction
Hedge Fund Positioning: AVBP
2026 Q2 Stats Unlock in 19 days 136 + Investors

Track Smart Money conviction in AVBP. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 136 120 13.33%
13F Shares 43M 40M 5.33%
Total Value $980M $817M 19.95%
New Positions 33 30 +3
Increased Positions 58 41 +17
Closed Positions 17 14 +3
Reduced Positions 25 34 -9
Total Calls 3 1 200.0%
Total Puts 3 0 100%
PUT/CALL Ratio 1.0 0.0 Neutral

Statistics: AVBP

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

136 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in AVBP. Verified SEC 13F-HR filings.

QUARTER:
Top 25 AVBP holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 General Catalyst Group Management, LLC 18.79% 1,494,786 $34.5M
2 Infinitum Asset Management, LLC 11.95% 4,148,923 $95.7M
3 Hhlr Advisors, LTD. 5.42% 3,929,117 $90.6M
4 Octagon Capital Advisors LP 5.03% 1,971,054 $45.5M
5 Novo Holdings A/S 3.63% 1,942,142 $44.8M
6 Suvretta Capital Management, LLC 2.59% 4,401,083 $101.5M
7 Vivo Capital, LLC 1.71% 885,916 $20.4M
8 Sofinnova Investments, Inc. 1.49% 1,696,752 $39.1M
9 Orbimed Advisors LLC 1.38% 3,027,328 $69.8M
10 Fund 1 Investments, LLC 1.32% 499,990 $11.5M
11 Squadron Capital Management LLC 0.93% 110,000 $2.5M
12 HSG Holding Ltd 0.86% 663,308 $14.0M
13 Sectoral Asset Management Inc 0.60% 30,013 $720K
14 Logos Global Management LP 0.40% 350,000 $8.1M
15 Seven Fleet Capital Management LP 0.37% 50,252 $1.2M
16 Polymer Capital Management (HK) LTD 0.24% 122,276 $2.8M
17 Moody Aldrich Partners LLC 0.23% 56,088 $1.3M
18 Jones Hill Capital LP 0.23% 45,809 $1.1M
19 Optimize Financial Inc 0.21% 18,916 $436K
20 Affinity Asset Advisors, LLC 0.21% 175,000 $4.0M
21 IvyRock Asset Management (HK) Ltd 0.21% 16,000 $369K
22 ADAR1 Capital Management, LLC 0.19% 141,814 $3.3M
23 Burkehill Global Management, LP 0.11% 100,000 $2.3M
24 Virtus Investment Advisers, LLC 0.07% 11,165 $258K
25 Persistent Asset Partners Ltd 0.07% 8,108 $187K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Arrivent Biopharma Inc (AVBP)

Is it too late to buy Arrivent Biopharma Inc (AVBP) following the 2026 Q2 hedge fund 13F filings?

Since the quarter end (June 30, 2026), AVBP has gained -11.7% vs +3.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →